Eight Advisory Avocats advises LXO Group on the tax aspects of the acquisition of the drug Nimotop from Bayer

Eight Advisory Avocats advises Laboratoire X.O (LXO Group), an international pharmaceutical company of French origin, on the acquisition of the commercialisation rights for the drug Nimotop (nimodipine) from Bayer (outside mainland China). This strategic transaction strengthens LXO Group’s presence in the international pharmaceutical market.

Nimotop is widely prescribed for the treatment of vasospasm following cerebral haemorrhage and is marketed in more than 45 countries. This acquisition contributes significantly to the expansion of the LXO Group’s international reach and enriches its product portfolio in the therapeutic areas of the central nervous system and the cardiovascular system. This creates synergies and diversifies the overall portfolio of the LXO Group.

This acquisition demonstrates LXO Group’s commitment to maintaining and expanding access to products that are important to patient health on a global scale. LXO Group currently offers 28 brands through a distribution network in over 80 countries. The LXO Group team has proven time and again that it is able to integrate and revitalise mature brands from large pharmaceutical companies while driving organic growth through its lifecycle management strategy, even for products that have historically been in decline.

“We are proud to have supported LXO Group in this strategic acquisition of Nimotop from Bayer. This transaction strengthens LXO Group’s position on the international stage and underlines our commitment to support our clients in their growth and innovation projects in the pharmaceutical sector,” said Hubert Christophe, Partner at Eight Advisory Avocats.

Eight Advisory Avocats participants in this transaction:

• Hubert Christophe, Partner, Attorney-at-law, Guillaume Exerjean, Jérémy Cosma and Julia Pizzetta, Attorneys-at-law